Immutep Reports 'Excellent' Median Overall Survival in Efti-Keytruda Combo Trial; Shares Rise

MT Newswires Live
05-05

Immutep (IMMP) said Monday that a phase 2b trial evaluating eftilagimod alfa in combination with Merck's (MRK) Keytruda to treat head and neck squamous cell cancer produced an "excellent" median overall survival result of 17.6 months.

The firm said the result "compares favorably" with to historical results from the two current standard-of-care approaches, while the drug combination was well-tolerated with no new safety signals.

Immutep said it has requested a meeting with the US Food and Drug Administration to discuss next steps including potential paths to approval.

Immutep shares rose nearly 13% in recent premarket activity.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10